PAH is a rare, life-threatening disorder marked by considerable morbidity and mortality. Despite the availability of a wide array of drugs for PAH, substantial unmet need remains for more-effective, more-tolerable agents. Based on our survey results and physician interviews, we discuss the relative attractiveness of various drug attributes and the implications for PAH drug development. In our conjoint analysis, we reveal the key trade-offs that surveyed cardiologists and pulmonologists are willing to make when considering new treatment options for PAH. Understanding the influence of key efficacy, safety/tolerability, and nonclinical attributes on physicians’ prescribing behavior can pave the way to commercial success in this competitive landscape.
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 U.S. and 32 European cardiologists and pulmonologists fielded in June 2020.
Key companies: Actelion, Bayer, Eli Lilly, Gilead, GlaxoSmithKline, Johnson & Johnson, Pfizer, United Therapeutics.
Key drugs: Adempas, Uptravi, Opsumit, remodulin/epoprostenol, Tyvaso/ventavis, Orenitram, Tadalafil.